Liquidseq Colorectal Cancer Panel [71 Genes]
About Liquidseq Colorectal Cancer Panel [71 Genes]
| Field | Value |
|---|---|
| Also Known As | ctDNA colorectal cancer panel, liquid biopsy colorectal panel, cfDNA CRC panel, CRC gene panel (blood-based) |
| Sample Type | Peripheral venous blood (plasma) |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with known or suspected colorectal cancer; both genders; typically used in advanced or metastatic disease and for recurrence monitoring |
| Price | Starting at ₹69600 |
What Is a Liquidseq Colorectal Cancer Panel [71 Genes]?
The Liquidseq Colorectal cancer panel [71 genes] is a specialised blood-based genetic test that analyses circulating tumour DNA (ctDNA) from a plasma sample. Using next-generation sequencing (NGS), a high-throughput DNA reading technology, it scans approximately 71 genes associated with colorectal cancer for mutations. Doctors use this panel to guide treatment decisions, monitor therapy response, and detect disease recurrence without requiring an invasive tissue biopsy.
What Does a Liquidseq Colorectal Cancer Panel [71 genes] Measure?
This panel examines small fragments of tumour DNA circulating in the bloodstream and looks for mutations across 71 cancer-related genes. The following are some of the key genes included in the panel.
| Gene | Role in Colorectal Cancer |
|---|---|
| APC | A major tumour suppressor gene primarily linked to colorectal cancer syndromes (FAP) is evaluated in broad solid tumour panels for general cell-cycle deregulation. |
| KRAS | Oncogene mutations are among the earliest events in colorectal cancer development |
| TP53 | The primary guardian of the genome acts as a master tumour suppressor. Mutations provide vital prognostic data regarding tumour aggressiveness across multiple cancer types. |
| ATM | A critical DNA damage-sensing kinase; germline mutations significantly elevate breast cancer susceptibility. |
| AKT1 | Core component of the PI3K/Akt/mTOR pathway; specific mutations (like E17K) are actionable targets in breast cancer. |
| ACVR1B | It's involved in the TGF-beta signalling pathway and regulates cell growth and differentiation |
| ATP6V0D2 | It's involved in cellular processes; its role in colorectal cancer is under active study |
The panel also assesses tumour mutation burden (TMB) and microsatellite instability (MSI), both of which can influence treatment choices.
Why Is a Liquidseq Colorectal Cancer Panel [71 Genes] Done?
Doctors order this panel to better understand the genetic profile of a patient's colorectal cancer and to guide targeted therapy decisions. Below are the key reasons it may be recommended.
Common Symptoms That May Require This Test
Your doctor may order this test if you present with symptoms associated with colorectal cancer. These include:
- Persistent changes in bowel habits such as diarrhoea, constipation, or narrowing of the stool
- Blood in the stool, whether bright red or dark and tar-like
- Abdominal cramps, pain, or bloating that does not resolve
- Unexplained weight loss
- Persistent fatigue or anaemia without a clear cause
- A confirmed diagnosis of colorectal cancer requiring molecular profiling for treatment planning
Conditions This Test Can Help Detect
The Liquidseq colorectal cancer panel is used in several clinical situations. These include:
- Advanced or metastatic colorectal cancer requiring targeted therapy selection
- Detection of actionable mutations to identify eligibility for anti-EGFR therapies
- Acquired resistance to ongoing treatment
- Minimal residual disease (MRD) after surgery or therapy, meaning a small number of cancer cells that may remain after treatment
- Assessment of the overall tumour genomic profile for treatment planning
Liquidseq Colorectal Cancer Panel [71 Genes] for Chronic Disease Monitoring
This panel has an established role in ongoing cancer monitoring. ctDNA levels in the blood can reflect how a tumour is responding to treatment, and this test may be repeated at intervals to track changes. It can help detect emerging resistance mutations early and assess whether minimal residual disease is present after surgery or systemic therapy.
How to Prepare and What to Expect
No complex preparation is needed for this test. The steps are straightforward, and the sample collection process is the same as a routine blood draw.
Do You Need to Fast?
No, fasting is not required. This test analyses DNA from your blood, and food or drink does not affect the results. You may eat and drink normally before your appointment.
Practical Tips Before Your Test
A few simple steps can help ensure a smooth experience and accurate results.
- Bring a detailed clinical history including your symptoms, previous test results, and any prior cancer diagnoses, as this is required for the test
- Inform your doctor and the lab about all medications, vitamins, and supplements you are currently taking
- Stay well-hydrated before your appointment, as this makes blood collection easier
- Wear clothing with sleeves that roll up easily to allow access to the arm
- No dietary restrictions are needed
Step-by-Step Procedure
The Liquidseq Colorectal cancer panel [71 genes] test procedure involves the following steps:
- A trained phlebotomist (a person who draws blood) collects a peripheral venous blood sample from your arm using a standard needle.
- The blood is processed in the laboratory to separate plasma, the liquid part of the blood, from the blood cells.
- Cell-free DNA (cfDNA), including ctDNA shed by tumour cells, is extracted from plasma.
- The extracted DNA undergoes next-generation sequencing, which reads and decodes the DNA fragments at high speed.
- The sequencing output is analysed for single-nucleotide variants, copy number changes, gene fusions, TMB, and MSI across all 71 genes.
- Molecular pathologists review the findings and prepare a detailed report, which is delivered within 30 days.
Factors That Can Affect Accuracy
Several factors may influence how reliably the test detects mutations.
- Cancer stage and tumour size: earlier-stage tumours shed less DNA into the bloodstream, making detection harder
- Tumour type and differentiation: moderately and poorly differentiated tumours typically shed more ctDNA
- Time between sample collection and laboratory processing
- Proper sample handling and storage during transport
- Recent chemotherapy or surgery, which can temporarily alter ctDNA levels in the blood
Understanding Your Liquidseq Colorectal Cancer Panel [71 Genes] Results
Results from this panel are not reported as numerical values. Instead, they describe which mutations, if any, were found. Your oncologist will interpret findings in the context of your full medical history and current treatment plan.
| Finding | Interpretation |
|---|---|
| No pathogenic variants detected | No cancer-associated mutations identified in the genes tested |
| Pathogenic or likely pathogenic variant detected | One or more clinically significant mutations found; specific genes and variants are reported |
| Variant of uncertain significance (VUS) | A genetic change whose clinical meaning is not yet established |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain clinical situations can affect how results are interpreted. In early-stage colorectal cancer, ctDNA concentrations in the blood may be very low, potentially falling below the test's detection threshold. This means a negative result does not completely rule out cancer.
Patients who have recently undergone surgery may experience a temporary rise in non-tumour DNA in the bloodstream, which can interfere with ctDNA detection. Similarly, recent chemotherapy or targeted therapy can transiently alter ctDNA levels, and your doctor will take this into account when reviewing your results.
How to Maintain Healthy Levels
While this test is used in a clinical cancer management setting, it remains important to support your overall health. These are general wellness tips, not a substitute for your treatment plan.
- Follow a diet rich in fibre, fruits, and vegetables, and limit intake of processed or red meats
- Maintain a healthy body weight and engage in regular physical activity as advised by your doctor
- Attend all follow-up appointments and screenings recommended by your oncologist
Lupin Diagnostics Liquidseq Colorectal Cancer Panel [71 Genes] Price
The Liquidseq colorectal cancer panel price at Lupin Diagnostics starts at ₹69,600. This test requires a visit to a Lupin Diagnostics centre; home collection is not available.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 69600 |
| Pune | 69600 |
| Bangalore | 69600 |
| Chennai | 69600 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Booking the LiquidSeq colorectal cancer panel online at Lupin Diagnostics is straightforward.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within 30 days.
Frequently Asked Questions
A liquid biopsy is a non-invasive test that detects tumour DNA released into the bloodstream, known as ctDNA. The Liquidseq colorectal cancer panel specifically targets approximately 71 genes commonly mutated in colorectal cancer, providing a genetic picture of the tumour without the need for a surgical tissue biopsy.
A traditional tissue biopsy requires surgical removal of a tumour sample. This blood-based panel is less invasive, easier to repeat over time, and can capture mutations across different tumour areas rather than just a single site. However, tissue biopsy remains the standard for the initial diagnosis of cancer.
This panel is typically recommended for adults with advanced or metastatic colorectal cancer, or for those where tissue is unavailable for molecular testing. It is also used to monitor treatment response and detect resistance mutations or residual disease after therapy.
The procedure involves a standard blood draw from a vein in your arm. The blood is then processed in a specialised laboratory, where ctDNA is extracted from plasma and analysed using NGS. The entire process is handled by trained technologists and molecular pathologists.
Not necessarily. In early-stage cancers or when the tumour is small, ctDNA levels in the blood may be too low to detect. A negative result should always be discussed with your oncologist, who will consider it alongside imaging, tissue biopsy, and other clinical findings.
Results for the Liquidseq colorectal cancer panel are typically delivered within 30 days. The NGS analysis and expert review of the data take time to ensure accuracy and clinical relevance.
Yes, this is one of its primary clinical uses. Identifying specific mutations, such as KRAS status or MSI, can determine eligibility for targeted therapies. Your oncologist will use the report findings alongside other clinical information to plan or adjust your treatment. Always follow your doctor's guidance regarding treatment options.
Liquidseq Colorectal Cancer Panel [71 Genes]
